Advertisement

Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency

  • Joseph Ciccolini
  • Cedric MercierEmail author
  • Laetitia Dahan
  • Alexandre Evrard
  • Jean-Christophe Boyer
  • Karine Richard
  • Jean-Philippe Dales
  • Alain Durand
  • Gerard Milano
  • Jean-François Seitz
  • Bruno Lacarelle
Short Communication

Abstract

This report here is the case of a 52-year-old male patient who suffered from extremely severe haematological toxicities (G4 neutropenia, G4 thrombocytopenia) while undergoing Xelox (Xeloda + Oxaliplatin) treatment for his multifocal hepatocarcinoma. Despite appropriate supportive treatment, his condition quickly deteriorated and led to death. It was hypothesized that dihydropyrimidine deshydrogenase (DPD) gene polymorphism could be, at least in part, responsible for this fatal outcome. To test this hypothesis, both phenotypic and genotypic studies were undertaken, and fully confirmed the DPD-deficient status of this patient. Uracil to dihydrouracil ratio in plasma was evaluated as a surrogate marker for DPD deficiency, and showed values out of the range previously recorded from a reference, non-toxic population. Interestingly, the canonical IVS14+1G>A single nucleotide polymorphism, usually associated with the most severe toxicities reported with 5-fluorouracil (5-FU), was not found in this patient, but further investigations showed instead a heterozygosity for the 1896C>T mutation located in the exon 14 of the DPYD gene. Taken together, the data strongly suggest for the first time that a toxic-death case after capecitabine-containing protocol could be, at least in part, linked with a DPD-deficiency syndrome. The case reported here warrants therefore systematic detection of patients at risk, including when oral capecitabine is scheduled.

Keywords

Capecitabine Oxaliplatin Gene polymorphism Dihydropyrimidine deshydrogenase 

References

  1. 1.
    Ezzeldin H, Diasio R (2004) Dihydropyrimidine dehydrogenase (DPD) deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 4:181–189PubMedCrossRefGoogle Scholar
  2. 2.
    Van Kuilenburg AB (2004) Dihydropyrimidine dehydrogenase (DPD) and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40(7):939–950PubMedCrossRefGoogle Scholar
  3. 3.
    Saif MW, Wood TE, McGee PJ, Diasio RB (2004) Peripheral neuropathy associated with capecitabine. Anticancer Drugs 15(8):767–771PubMedCrossRefGoogle Scholar
  4. 4.
    Hooiveld EA, van Kuilenburg AB, Haanen JB, Westermann AM (2004) Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase (DPD) deficiency. Ned Tijdschr Geneeskd 148(13):626–628PubMedGoogle Scholar
  5. 5.
    Fischel JL, Formento P, Renée N, Etienne MC, Milano G (2004) Experimental arguments for a better understanding of hand-foot syndrome under capecitabine. Presented at the American Association of Cancer Research 95th Meeting, Orlando, FL, April 2004Google Scholar
  6. 6.
    Ciccolini J, Evrard A, Cuq P (2004) Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story. Curr Med Chem Anti-Canc Agents 4(2):71–81CrossRefGoogle Scholar
  7. 7.
    Jiang H, Lu J, Jiang J, Hu P (2004) Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics. J Clin Pharmacol 44:1260–1272PubMedCrossRefGoogle Scholar
  8. 8.
    Ciccolini J, Mercier C, Blachon MF, Favre R, Durand A, Lacarelle B (2004) A simple and rapid high performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. J Clin Pharm Ther 29:309–315CrossRefGoogle Scholar
  9. 9.
    Ciccolini J, Etienne-Grimaldi MC, Renée N, Formento JL, Lacarelle B, Milano G (2005) Comparison of different approaches for predicting dihydropyrimidine deshydrogenase (DPD) deficiency in cancer patients: enzymatic activity in lymphocytes versus uracil/dihydrouracil (U/UH2) ratio in plasma versus IVS14+1G>A mutation screening. Presented at the American Association of Cancer Research 96th Meeting, Anaheim, CA, 16–20 April 2005Google Scholar
  10. 10.
    Nauck M, Gierens H, Marz W, Wieland H (2001) Rapid detection of a common dihydropyrimidine dehydrogenase (DPD) mutation associated with 5-fluorouracil (5-FU) toxicity and congenital thymine uraciluria using fluorogenic hybridisation probes. Clin Biochem 34(2):103–105PubMedCrossRefGoogle Scholar
  11. 11.
    Ezzeldin H, Okamoto Y, Johnson MR, Diasio RB (2002) A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase (DPD) deficiency. Anal Biochem 306(1):63–73PubMedCrossRefGoogle Scholar
  12. 12.
    Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH (2002) High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase (DPD) gene of patients with severe 5-fluorouracil (5-FU)-associated toxicity. Pharmacogenetics 12(7):555–558PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Joseph Ciccolini
    • 1
  • Cedric Mercier
    • 2
    Email author
  • Laetitia Dahan
    • 3
  • Alexandre Evrard
    • 4
  • Jean-Christophe Boyer
    • 4
  • Karine Richard
    • 3
  • Jean-Philippe Dales
    • 5
  • Alain Durand
    • 1
  • Gerard Milano
    • 1
  • Jean-François Seitz
    • 3
  • Bruno Lacarelle
    • 1
  1. 1.Clinical Pharmacokinetics DepartmentLa Timone University HospitalMarseilleFrance
  2. 2.Medical Oncology UnitLa Timone University HospitalMarseille cedex 05France
  3. 3.Gastroenterology UnitLa Timone University HospitalMarseilleFrance
  4. 4.Clinical Biochemistry and Toxicology DepartmentCaremeau General Hospital NîmesFrance
  5. 5.Anatomopathology DepartmentNorthern School of MedicineMarseilleFrance

Personalised recommendations